Breaking Finance News

Needham disclosed Boston Scientific (NYSE:BSX), hiking its price target to $32.00 earlier today

Reporting a potential upside of 0.15%, Needham upped the price target of Boston Scientific (NYSE:BSX) to $32.00

On 6/16/2017, Wells Fargo Company released a statement for Boston Scientific (NYSE:BSX) bumped up the target price from $29.50 to $31.00 that suggested an upside of 0.12%.

Boasting a price of $27.91, Boston Scientific (NYSE:BSX) traded 0.21% higher on the day. With the last stock price close up 9.77% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Boston Scientific has recorded a 50-day average of $27.09 and a two hundred day average of $26.43. Volume of trade was down over the average, with 4,497,906 shares of BSX changing hands under the typical 5,652,450

Performance Chart

Boston Scientific (NYSE:BSX)

With a total market value of $0, Boston Scientific has price-earnings ratio of 51.90 with a one year low of $19.67 and a one year high of $29.40 .

In addition to Needham reporting its stock price target, a total of 26 brokers have released a research note on Boston Scientific. The 12-month price target is $24.46 with 0 firms rating the stock a strong buy, 0 equity analysts rating the company a buy, zero equity analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Boston Scientific (NYSE:BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.